Reaxys
Quote
Structure & Reaction Searching
•  95% of all papers are junk. … What the
author considers important in a paper is
irrelevant. Read the whole paper and make
up your own mind. CHEM 23201
Fall 2016
•  John Cornforth, University of Sussex, email
communication on Apr. 6, 2005.
Open Reaxys
10/11/16
CHEM 23201.08
2
Overview
•  Assignment 5
•  Presentation
•  Reaxys Practice
ASSIGNMENT 5
10/11/16
CHEM 23201.08
3
10/11/16
CHEM 23201.08
4
Assignment 5 - Reaxys
SciFinder vs Reaxys
•  Due – after fall break
–  Questions 4-6
•  Record the Reaction ID with the highest yield
•  Easy to do vs Hard to do
–  No yield data – then pick any reaction
•  Impossible vs Possible
•  Q5 – Synthesis Planner example
•  Q6 – Citation for RefWorks
10/11/16
CHEM 23201.08
5
10/11/16
CHEM 23201.08
6
RefWorks tip
Attach any document to the record in RefWorks The document can be
Article pdf
Word document
Excel spreadsheet
PowerPoint slides
Screen shot
etc.
10/11/16
PRESENTATION
CHEM 23201.08
7
10/11/16
CHEM 23201.08
Presentation
8
Show study results
•  Suggestions
•  Connection to something learned in Gen. Chem. or Org.
Chem.
•  Interesting synthesis
–  Include at least 3 steps
•  Spectra - if you describe a synthesis/isolation
•  Interesting use (bioremediation, nutrition, industrial, etc.)
–  Explain the chemistry
•  Conformation that effects what it does
•  Avoid the clinical listing of symptoms
–  Explain chemistry for the cause/prevention of the symptom
–  Explain study results
10/11/16
CHEM 23201.08
Hatjiharissi, E. Blood 2007
9
10/11/16
CHEM 23201.08
Show study results
From www.bloodjournal.org by guest on October 5, 2016. For
From www.bloodjournal.org by guest on October 5, 2016. For personal use only.
BLOOD, 1 OCTOBER 2007 ! VOLUME 110, NUMBER 7
100
Fc!RIIIA-158 VARIANTS AND RITUXIMAB ACTIVITY
B
ADCC Against ARH-77 Cells
VV
VF
FF
40
20
VF
FF
40
100
B
ADCC Against ARH-77 Cells
80
5:1
20:1
2.5:1
10:1
5:1
2.5:1
Effector to Target Cell Ratio
D
80
70
50
VV
VF
40
FF
30
% cytotoxicity (20:1)
100
60
80
60
VV
VF
FF
60
% Cytotoxicity
10:1
Effector to Target Cell Ratio
VV
VF
FF
40
R2 = 0.6037
20
0
10
60
40
40
20
20
0
20
100
80
0
20:1
40
80
120
160
200
CD16 receptors (10^3)
10
50
100
200
RTX Concentration (ug/ mL)
20:1
Figure 2. Characterization of NK-cell RTX-binding and RTX-mediated ADCC activity by NK cells against Daudi and ARH-77 CD20! B cells. RTX-mediated ADCC
activity by NK cells against (A) ARH-77 and (B) Daudi CD20# B cells was assayed for 9 donors whose genotyping demonstrated Fc!RIIIa-158 V/V (n $ 3), V/F (n $ 3), and F/F
(n $ 3) and (C) NK-cell RTX binding. (D) The correlation between cell-surface CD16 receptors and RTX-dependent ADCC activity for these individuals.
Hatjiharissi, E. Blood 2007
Authorship
10/11/16
CHEM 23201.08
clinical responses among rituximab-refractory patients expressing Fc!RIIIa-158 F/F.14 Further exploration of agents aimed at
augmenting CD16 expression, particularly in context with
newer CD20-directed mAb-bearing enhanced Fc binding and
ADCC activity,15,16 may lead to improved responses among
patients with indolent NHL, including for those individuals
expressing Fc!RIIIa-158 F/F.
In summary, the results of these studies suggest that individuals
expressing at least one valine at Fc!RIIIa-158 might in part have
better clinical outcomes due to increased CD16 expression.
Contribution: E.H. designed the study, performed research,
analyzed the data, and wrote the first draft of the manuscript;
L.X., designed, performed, and analyzed experiments in molecular biology; D.D.S, performed various pertinent research; Z.R.H.,
collected samples and analyzed the data; B.T.C. performed
various pertinent research; S.V. and M.M. designed, performed,
and analyzed experiments in molecular biology; Y.C. performed
various pertinent research; R.J.M. collected samples and analyed
the data; X.L. performed various pertinent research; E.A.D.
collected samples and analyzed the data; A.K., C.M., and
K.C.A. contributed advice to the design and interpretation of the
study; E.A.F. designed, performed, and analyzed experiments in
10:1
5:1
20:1
2.5:1
Effector to Target Cell Ratio
11
C
80
10/11/16
70
D
Hatjiharissi, E. Blood 2007
CHEM 23201.08
50
40
30
20
12
100
60
RTX Binding
agents known to up-regulate CD16, including one study wherein
the addition of IL-2 to rituximab appeared to selectively result in
0
0
0
VV
VF
FF
% cytotoxicity (20:1)
RTX Binding
A
VV
60
20
0
C
Fc!R
ADCC Against Daudi Cells
80
60
% Cytotoxicity
% Cytotoxicity
80
100
Show study results
BLOOD, 1 OCTOBER 2007 ! VOLUME 110, NUMBER 7
2563
% Cytotoxicity
A
10
80
60
40
20
0
Presentation – Sources used
Presentation
–  Don’t rely on just the web or encyclopedias
•  Web & encyclopedias are a good place to start
•  Verify information with articles or patents
•  Peer Evaluation
–  Foreign language journals
•  Do you read the language?
•  Did you get the article via ILL?
•  After Action Report
–  Top tier sources
•  Slides from two presentations
10/11/16
CHEM 23201.08
•  ACS, RSC or other professional society journals
•  Nature, Science, Proc. National Academy of Sciences
•  Document Type: Review articles
13
10/11/16
Presentation Tips
CHEM 23201.08
14
YouTube videos
•  Speak up
•  How does your tone indicate or reinforce a
question, a statement and a command?
–  For the entire sentence
•  Don’t “swallow” your sentence
•  What is the presenter's view of upvoice in
the workplace?
•  Don’t read your presentation
•  Look at everyone
•  It is ok to be nervous
•  Between 1:00 and 1:50, how many times do
you hear upvoice? –  Practice, practice, practice
–  Know your subject
–  Anticipate questions or problems
10/11/16
CHEM 23201.08
•  Do you have upvoice?
15
10/11/16
CHEM 23201.08
16
Sound of your voice ≠ What you say
Presentation Tips
Lacks confidence
•  Our Speech is Infected with…
Afraid of Silence
–  “Like”
–  “Ya know”
–  Up Voice
Bored with topic
•  Sounds like a question when it isn’t
–  Example: “Here is the Carbon NMR.”
•  Taylor Mali
–  (http://www.youtube.com/watch_popup?v=V9x5KhfWAis&vq=medium)
10/11/16
CHEM 23201.08
Shellenbarger, Sue. Is this how
you really talk? Your voice
affects others’ perceptions. Wall
Street Journal. 24 April 2013,
D1, D3
17
10/11/16
CHEM 23201.08
18
Presentation - Slides
Summary
•  Don’t… –  Speed through a slide
–  Talk about the previous slide
–  Backup then go forward
•  Assignment #5
•  Presentation Tips
•  Reaxys practice
•  Do
–  Make duplicate slides, if needed
–  Know how to select by slide number
•  <slide #> <enter>
–  Hide the screen
•  <b>
10/11/16
CHEM 23201.08
19
10/11/16
CHEM 23201.08
20
Sound of your voice ≠ What you say
Presentation - Slides
Lacks confidence
•  Don’t… Afraid of Silence
–  Speed through a slide
–  Talk about the previous slide
–  Backup then go forward
Bored with topic
•  Do
–  Make duplicate slides, if needed
–  Know how to select by slide number
•  <slide #> <enter>
Shellenbarger, Sue. Is this how
you really talk? Your voice
affects others’ perceptions. Wall
Street Journal. 24 April 2013,
D1, D3
–  Hide the screen
•  <b>
10/11/16
CHEM 23201.08
21
10/11/16
CHEM 23201.08
22
Presentation - Slides
Summary
•  Don’t… –  Speed through a slide
–  Talk about the previous slide
–  Backup then go forward
•  Assignment #5
•  Presentation Tips
•  Reaxys practice
•  Do
–  Make duplicate slides, if needed
–  Know how to select by slide number
•  <slide #> <enter>
–  Hide the screen
•  <b>
10/11/16
CHEM 23201.08
23
10/11/16
CHEM 23201.08
24
Presentation - Slides
Summary
•  Don’t… –  Speed through a slide
–  Talk about the previous slide
–  Backup then go forward
•  Assignment #5
•  Presentation Tips
•  Reaxys practice
•  Do
–  Make duplicate slides, if needed
–  Know how to select by slide number
•  <slide #> <enter>
–  Hide the screen
•  <b>
10/11/16
CHEM 23201.08
25
Reaxys Practice
10/11/16
CHEM 23201.08
27
10/11/16
CHEM 23201.08
26